Publications

An exploration of how broadly neutralizing antibodies might induce HIV remission: the 'vaccinal' effect.

Tipoe T. et al, (2022), Curr opin hiv aids, 17, 162 - 170

BreakAlign: a Perl program to align chimaeric (split) genomic NGS reads and allow visual confirmation of novel retroviral integrations.

Marchi E. et al, (2022), Bmc bioinformatics, 23

The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial.

Lee MJ. et al, (2022), Trials, 23

A simple, robust flow cytometry-based whole blood assay for investigating sex differential interferon alpha production by plasmacytoid dendritic cells.

Sampson O. et al, (2022), J immunol methods, 504

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Tomic A. et al, (2022), Nat commun, 13

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.

COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium. Electronic address: julian.knight@well.ox.ac.uk None. and COvid-19 Multi-omics Blood ATlas (COMBAT) Consortium None., (2022), Cell, 185, 916 - 938.e58

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.

Ogbe A. et al, (2022), Jci insight

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.

Zacharopoulou P. et al, (2022), Sci rep, 12

SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2022), Cell

Human MAIT cells respond to and suppress HIV-1.

Phetsouphanh C. et al, (2021), Elife, 10

Immunotherapeutic approaches to HIV cure and remission

Lee MJ. et al, (2021), Current opinion in infectious diseases, Publish Ahead of Print

An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults.

Adriano Vieira V. et al, (2021), Plos pathog, 17

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne RP. et al, (2021), Cell

Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish the rare phenotype of elite control in adolescents living with HIV from viraemic non-progressors.

Vieira VA. et al, (2021), Aids

No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach.

Alagaratnam J. et al, (2021), J virus erad, 7

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Frater J. et al, (2021), Lancet hiv, 8, e474 - e485

Divergent trajectories of antiviral memory after SARS-Cov-2 infection

Tomic* A. et al, (2021)

Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection

Frater J. et al, (2021)